What do pharmaceuticals really cost in the long run?

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Drug Pricing Analysis

Background:

• Branded drug prices are often evaluated at launch, potentially not reflecting long-term value.
• Generic competition significantly impacts drug prices over a product's lifecycle.
• Pharmaceuticals can generate medical cost offsets, influencing net healthcare expenditure.

Purpose of the Study:

• To estimate the long-run average cost (LAC) of a typical drug.
• To assess the impact of generic competition on drug pricing.
• To incorporate medical cost offsets into the estimation of drug costs.

Main Methods:

• Descriptive analysis of retrospective cross-sectional survey data.
• Estimation of LAC using discounted average price per unit over the drug lifecycle.
• Inclusion of generic competition and medical cost offsets in the analysis.

Main Results:

• Brand drug prices were 39% higher than LAC pre-generic entry, and 75% higher when accounting for medical cost offsets.
• Launch prices were 11% above LAC, and 40% above LAC net of offsets.
• Average market-weighted prices declined rapidly post-generic entry.

Conclusions:

• Branded drug prices may overstate true long-run pharmaceutical costs by 40-75%.
• Policy decisions regarding market access should consider full long-term costs, not just launch prices.
• Accurate cost assessment is crucial for ensuring valuable drugs enter the market.